BioNTech's ADC Candidate Delivers Robust Data, Setting 2026 Filing in Motion

BioNTech’s strategic pivot from pandemic hero to oncology contender is gaining tangible momentum. New clinical results for a key cancer drug candidate have not only impressed analysts but have also set a clear regulatory timeline, with the company’s first-ever oncology marketing application now slated for 2026.

The data, presented at the SGO Annual Meeting in San Juan, center on the antibody-drug conjugate (ADC) trastuzumab pamirtecan, also known as BNT323 or DB-1303. In a Phase 2 trial involving 145 heavily pre-treated patients with HER2-expressing advanced or recurrent endometrial cancer, the confirmed objective response rate was 47.9%. For the critical subgroup of patients previously treated with checkpoint inhibitors, the overall response rate was even higher at 49.3% among 73 evaluated participants.

These figures starkly outperform standard chemotherapy, which typically achieves a response rate of around 15% in this patient population. The ADC candidate also doubled the median progression-free survival to 8.1 months, compared to approximately four months with chemo, while the median duration of response was 10.3 months. Efficacy was observed across all levels of HER2 expression, a notable finding that suggests potential benefit for patients with lower tumor expression who see limited gains from existing therapies.

Bank of America Securities responded to the robust dataset by nudging its price target for BioNTech shares from $128 to $130, maintaining a Buy rating. The bank acknowledged that the direct commercial opportunity in second-line endometrial cancer is modest, contributing only about $3 to its valuation. The broader strategic importance, however, is far greater. A successful approval would mark BioNTech’s first regulatory clearance in oncology and help establish the commercial infrastructure needed for its wider pipeline of cancer programs.

Should investors sell immediately? Or is it worth buying BioNTech?

The financial foundation for this multi-year transformation remains solid. The company ended 2025 with cash, cash equivalents, and securities totaling approximately €17.2 billion. This war chest is supporting a pipeline build-out that includes the global Phase 3 trial Fern-EC-01 for the same endometrial cancer indication, which is already underway. The planned Biologics License Application (BLA) submission to the U.S. FDA in 2026 is contingent on regulatory feedback.

BNT323, licensed from Shanghai-based DualityBio in April 2023 for $170 million upfront plus potential milestone payments of up to $1.5 billion, has already received Fast Track and Breakthrough Therapy designations from the FDA in 2023. The upcoming BLA filing represents the most concrete evidence yet that BioNTech's oncology strategy is accelerating.

The analyst community is broadly constructive. Of 18 analysts covering the stock, 13 recommend Buy and four suggest Hold, with a consensus price target of $133.13. Morgan Stanley rates the shares Overweight with a $126 target. A dissenting voice comes from Leerink Partners, which recently downgraded the stock to Market Perform and set a $113 price target.

BioNTech at a turning point? This analysis reveals what investors need to know now.

For 2026, BioNTech anticipates revenue between €2.0 billion and €2.3 billion, reflecting an expected decline of roughly 25% as COVID-related income continues to wane. This forecast underscores the company's transition toward a multi-product oncology portfolio. By year's end, BioNTech expects up to seven late-stage clinical data readouts, including interim results for mRNA-based cancer immunotherapies and other advanced candidates, signaling that its pipeline is moving into a decisive phase.

Ad

BioNTech Stock: New Analysis - 14 April

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69145160 |